Haipin Chen

Haipin Chen

Auto-generated profile, based on publicly available information

Haipin Chen

Department of Hematology‐Oncology Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases Hangzhou People's Republic of China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
HCHaipin Chen
Haipin Chen
MGMiner Gu
Miner Gu
JLJ.B. Liang
J.B. Liang
HSHua Song
Hua Song
JZJingying Zhang
Jingying Zhang
XXXiaojun Xu
Xiaojun Xu
While the prognostic role of immunoglobulin heavy chain locus (IGH) rearrangement in minimal residual disease (MRD) in pediatric B-acute lymphoblastic leukemia (B-ALL) has been reported, the contribution of light chain loci (IGK/IGL) remains elusive. This study is to evaluate the prognosis of IGH and IGK/IGL rearrangement-based MRD detected by next-generation sequencing in B-ALL at the end of induction (EOI) and end of consolidation (EOC). IGK/IGL rearrangements identify 5.5% of patients without trackable IGH clones. Concordance rates for IGH and IGK/IGL are 79.9% (cutoff 0.01%) at EOI and 81.0% (cutoff 0.0001%) at EOC, respectively. Patients with NGS-MRD < 0.01% at EOI or <0.0001% at EOC present excellent outcome, with 3-year event-free survival rates higher than 95%. IGH-MRD is prognostic at EOI/EOC, while IGK-MRD at EOI/EOC and IGL-MRD at EOI are not. At EOI, NGS identifies 26.2% of higher risk patients whose MRD < 0.01% by flow cytometry. However, analyzing IGK/IGL along with IGH fails to identify additional higher risk patients both at EOI and at EOC. In conclusion, IGH is crucial for MRD monitoring while IGK and IGL have relatively limited value.

16 June 2026 in HLA
Verified
Journal Article
Closed access
FJFenfen Jin
Fenfen Jin
FZFenying Zhao
Fenying Zhao
HCHaipin Chen
Haipin Chen
XXXiaojun Xu
Xiaojun Xu

24 October 2025 in HLA
Verified
Journal Article
Closed access
XGXiaomeng Gu
Xiaomeng Gu
HCHaipin Chen
Haipin Chen
FZFenying Zhao
Fenying Zhao
MGMiner Gu
Miner Gu
XXXiaojun Xu
Xiaojun Xu

12 February 2026 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
HCHaipin Chen
Haipin Chen
JMJing Miao
Jing Miao
LFLinyang Fan
Linyang Fan
JLJuan Liang
Juan Liang
JZJingying Zhang
Jingying Zhang
XXXiaojun Xu
Xiaojun Xu
Haipin Chen, M.M., Jing Miao, M.M., Linyang Fan, Ph.D., Juan Liang, Ph.D., Jingying Zhang, Ph.D., Weiqun Xu, Ph.D., Fenying Zhao, M.M., Diying Shen, Ph.D., Heping Shen, M.M., Hua Song, M.M., Shengchao Wu, M.M., Yongmin Tang, M.M., Tao Sun, Ph.D., and Xiaojun Xu, M.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2025.0486